ACP-5862 is a major active, circulating, pyrrolidine ring-opened metabolite of Acalabrutinib with an IC 50 of 5.0 nM for Bruton tyrosine kinase ( BTK ) . ACP‐5862 is a weak time‐dependent inactivator of CYP3A4 and CYP2C8 . Acalabrutinib is an orally active, irreversible, and highly selective BTK inhibitor , with an IC 50 of 3 nM and EC 50 of 8 nM.
Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > Drug Metabolite | Products > Signaling Pathways > Btk | Products > Signaling Pathways > Cytochrome P450
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.